U.S. markets open in 2 hours 26 minutes
  • S&P Futures

    4,169.25
    +11.50 (+0.28%)
     
  • Dow Futures

    34,327.00
    +71.00 (+0.21%)
     
  • Nasdaq Futures

    13,395.25
    +91.75 (+0.69%)
     
  • Russell 2000 Futures

    2,233.90
    +8.40 (+0.38%)
     
  • Crude Oil

    66.61
    +0.34 (+0.51%)
     
  • Gold

    1,869.00
    +1.40 (+0.07%)
     
  • Silver

    28.62
    +0.35 (+1.22%)
     
  • EUR/USD

    1.2216
    +0.0059 (+0.49%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.50
    +0.69 (+3.67%)
     
  • GBP/USD

    1.4195
    +0.0058 (+0.41%)
     
  • USD/JPY

    108.9910
    -0.2090 (-0.19%)
     
  • BTC-USD

    45,354.48
    +856.76 (+1.93%)
     
  • CMC Crypto 200

    1,262.19
    +64.28 (+5.37%)
     
  • FTSE 100

    7,060.65
    +27.80 (+0.40%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

3 Things to Cheer About in Abbott's Earnings Report

Adria Cimino, The Motley Fool
·3 min read
3 Things to Cheer About in Abbott's Earnings Report
  • Oops!
    Something went wrong.
    Please try again later.

Abbott Laboratories (NYSE: ABT) disappointed some investors after first-quarter revenue lagged behind analysts' estimates. Investors probably were hoping that Abbott's coronavirus diagnostics along with the strength of its star product -- the FreeStyle Libre continuous glucose monitoring system -- would offer revenue a bigger push. Abbott's revenue still rose more than 35% to $10.5 billion in the first quarter.